University of Ioannina
Επίδραση της θεραπείας με rimonabant ως μονοθεραπεία ή σε συνδυασμό με υπολιπιδαιμικά φάρμακα στις μεταβολικές παραμέτρους υπέρβαρων και παχύσαρκων ασθενών με δυσλιπιδαιμία
Abstract
dc:descriptionObjective: Obesity is a chronic condition, which is frequently associated with disorders of lipid metabolism. The present open-label randomized study evaluated the effects of rimonabant alone and in combination with fenofibrate or ezetimibe on anthropometric variables, lipid profile, carbohydrate metabolism, LDL and HDL phenotype and activities of atherosclerosis-related enzymes in overweight and obese patients [body mass index (BMI) = 27-40 kg/m2] with atherogenic dyslipidemia [triglycerides (TG) = 150-700 mg/dL and total cholesterol (TC)/high density lipoprotein cholesterol (HDL-C) ratio >5 in men and >4.5 in women].Methods: Sixty overweight and obese patients with atherogenic dyslipidemia were prescribed a low-calorie diet and were randomized to rimonabant 20 mg/d (R group), rimonabant 20 mg/d plus micronized fenofibrate 160 mg/d (RF group) or rimonabant 20 mg/d plus ezetimibe 10 mg/d (RE group) for 3 months. Anthropometric and metabolic parameters were assessed before treatment initiation and at 3 months.Results: Four patients dropped out. Significant reductions in blood pressure, body weight, BMI, waist circumference, TC, non-HDL-C, TG and TC/HDL-C ratio were observed in all treatment groups at 3 months. The reduction in TG and TC/HDL-C ratio was greater in RF group (p<0.05), whereas non-HDL-C reduction was greater in the combination treatment groups compared with rimonabant monotherapy (p<0.05). The levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein Β (apoB) decreased significantly only in RF and RE groups. The concentration of HDL-C increased in R and RF groups; this increase was greater in RF group. However, apoA1 levels increased only in RF group. Very low-density lipoprotein cholesterol (VLDL-C) and small, dense LDL-C (sdLDL-C) levels were significantly reduced in all treatment groups; both changes were more pronounced in RF group. Furthermore, similar significant reductions in the proportion of sdLDL-C over total LDL-C were observed in all groups. Finally, mean LDL particle diameter increased significantly with R and RF treatment. VLDL-C and sdLDL-C reductions were independently correlated with TG lowering in RF group and with LDL-C decrease in RE group in multivariate analysis. Large HDL-C levels increased significantly in all treatment groups, while this increase was more pronounced in RF group. The concentration of intermediate HDL-C increased significantly only in RF group, whereas small HDL-C levels were significantly reduced with R and RE administration and significantly increased with RF treatment. The elevations in the concentration of all HDL subclasses in RF group were positively correlated with the changes in HDL-C and TG levels during treatment. Lipoprotein-associated phospholipase A2 (LpPLA2) and non-HDL-LpPLA2 activities were significantly reduced in RE and RF groups. In contrast, HDL-LpPLA2 activity was significantly increased only with RF therapy. Paraoxonase 1 (PON1) activity against paraoxon was reduced in RF group, whereas PON1 activity against phenylacetate and PON1 (phenylacetate)/LDL-C ratio were significantly increased in R and RE groups. Leptin levels decreased significantly, while adiponectin concentration remained unaltered in all treatment groups. However, high molecular weight/total adiponectin ratio significantly increased in R group. Finally, visfatin concentration significantly decreased in the two combination treatment groups. Conclusions: Treatment with rimonabant improved the anthropometric parameters and the lipid profile in overweight and obese patients with atherogenic dyslipidemia. The combination of rimonabant with fenofibrate or ezetimibe was associated with further favorable changes in metabolic parameters, LDL and HDL phenotype and activities of atherosclerosis-related enzymes in these patients.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Florentin, Matilda
- Φλωρεντίν, Ματίλντα
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44422